PUBLISHER: The Business Research Company | PRODUCT CODE: 1948360
PUBLISHER: The Business Research Company | PRODUCT CODE: 1948360
Transmucosal drug delivery devices are medical instruments designed to administer drugs through mucous membranes, such as those found in the mouth, nose, or rectum, allowing for rapid absorption into the bloodstream. These devices are particularly useful for delivering medications that are poorly absorbed by the gastrointestinal tract or require swift onset of action, such as pain relief or hormone therapy. Their primary function is to circumvent the digestive system, offering a direct and efficient route for drug delivery.
The two main categories of transmucosal drug delivery devices are passive transmucosal drug delivery and active transmucosal drug delivery. Passive transmucosal drug delivery involves the absorption of drugs through mucous membranes without external energy or active transport mechanisms. Various types of products include buccal tablets, oral sprays, sublingual films, wafers, gels, medicated confectionery, among others, used for treating conditions such as pain management, addiction, and hormonal therapies. End users include academic and research institutions, pharmaceutical and biotechnology firms, diagnostic laboratories, and hospitals.
Tariffs are impacting the transmucosal drug delivery devices market by increasing costs of imported medical-grade polymers, microfabrication components, electronic control units, and precision manufacturing equipment. Pharmaceutical and biotechnology companies in North America and Europe are most affected due to reliance on specialized imported materials, while Asia-Pacific faces cost pressures on export-oriented device production. These tariffs are increasing manufacturing expenses and extending product development timelines. However, they are also encouraging domestic sourcing, localized device manufacturing, and investment in regional production facilities to improve supply chain resilience.
The transmucosal drug delivery devices market research report is one of a series of new reports from The Business Research Company that provides transmucosal drug delivery devices market statistics, including transmucosal drug delivery devices industry global market size, regional shares, competitors with a transmucosal drug delivery devices market share, detailed transmucosal drug delivery devices market segments, market trends and opportunities, and any further data you may need to thrive in the transmucosal drug delivery devices industry. This transmucosal drug delivery devices market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The transmucosal drug delivery devices market size has grown strongly in recent years. It will grow from $54.63 billion in 2025 to $59.61 billion in 2026 at a compound annual growth rate (CAGR) of 9.1%. The growth in the historic period can be attributed to expansion of non-invasive drug delivery approaches, rising demand for pain management therapies, increased use of hormone replacement treatments, growth in pharmaceutical formulation innovation, wider acceptance of transmucosal therapies.
The transmucosal drug delivery devices market size is expected to see strong growth in the next few years. It will grow to $81.52 billion in 2030 at a compound annual growth rate (CAGR) of 8.1%. The growth in the forecast period can be attributed to increasing development of personalized medicine solutions, rising investments in advanced drug delivery platforms, growing demand for at-home drug administration devices, expansion of biologics and peptide-based drugs, increased regulatory approvals for novel delivery systems. Major trends in the forecast period include increasing adoption of buccal and sublingual delivery formats, growing demand for rapid onset drug administration, expansion of microneedle and active delivery technologies, rising focus on patient-friendly drug delivery devices, enhanced emphasis on dose accuracy and bioavailability.
The increasing prevalence of chronic diseases is expected to drive the growth of the transmucosal drug delivery devices market in the coming years. Chronic diseases are long-lasting conditions that typically develop gradually and persist over time, often requiring ongoing medical management to control symptoms and prevent complications. The rise in chronic diseases can be attributed to factors such as lifestyle choices, aging populations, environmental influences, challenges within healthcare systems, and urbanization. Transmucosal drug delivery devices are employed in managing chronic diseases by providing controlled and efficient medication delivery, ensuring sustained therapeutic levels to manage symptoms and enhance patient adherence. For example, in August 2023, a report from the Leukemia & Lymphoma Society (LLS), a US-based nonprofit organization, indicated that in the US, a person is diagnosed with leukemia, lymphoma, or myeloma approximately every three minutes. In 2023, an estimated 184,720 individuals were expected to be diagnosed, accounting for 9.4% of the projected 1,958,310 new cancer cases for the year. Therefore, the rising prevalence of chronic diseases is fueling the growth of the transmucosal drug delivery devices market.
Leading companies in the transmucosal drug delivery devices sector are actively pursuing innovative solutions such as proprietary transdermal patch delivery platforms, which are designed to improve drug absorption, enhance patient compliance, and offer convenience. These platforms utilize specialized technologies owned by companies to administer medications through the skin, ensuring controlled release and optimized therapeutic outcomes. For example, in January 2024, Starton Therapeutics Inc., a US-based biotechnology firm, introduced STARSILON, a novel proprietary transdermal patch delivery platform. This platform is specifically designed to deliver difficult-to-formulate active pharmaceutical ingredients (APIs) over an extended period, thereby expanding the options for transdermal drug delivery and enhancing therapeutic efficacy through sustained release mechanisms.
In April 2023, Difgen Pharmaceuticals, an India-based pharmaceutical company, acquired Aveva Drug Delivery Services for an undisclosed sum. This strategic acquisition is intended to bolster Difgen Pharmaceuticals' drug delivery capabilities and incorporate advanced technologies into its pharmaceutical product portfolio. Aveva Drug Delivery Services, based in the US, specializes in manufacturing transdermal delivery systems (TDS) and oral dissolvable films (ODF).
Major companies operating in the transmucosal drug delivery devices market are Johnson & Johnson, Bayer AG, Sanofi SA, Bristol-Myers Squibb Company, Abbott Laboratories, Novartis AG, Viatris Inc., Teva Pharmaceutical Industries Ltd., Catalent Inc., AptarGroup, Glenmark Pharmaceuticals Limited, Stevanato Group S.p.A, Noven Pharmaceuticals, Antares Pharma Inc., Satsuma Pharmaceuticals Inc., AdvaCare Pharma LLP, Lifevision Healthcare Private Limited, SAVA Healthcare Limited, Kaizen Pharmaceuticals Pvt. Ltd., Maya Biotech Pvt. Ltd
North America was the largest region in the transmucosal drug delivery devices market in 2025. The regions covered in the transmucosal drug delivery devices market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the transmucosal drug delivery devices market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain
The transmucosal drug delivery devices market consists of sales of sublingual sprays, nasal drops, rectal suppositories, and sublingual tablets. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Transmucosal Drug Delivery Devices Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses transmucosal drug delivery devices market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for transmucosal drug delivery devices ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The transmucosal drug delivery devices market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.